From non-prescription to prescription pharmaceuticals

Constructed a general research laboratory (Takada Research Laboratory, Tokyo) (Sep.)

Constructed Ohta Plant

Start of the collaborative research with Kanazawa University on OK-432(now “Picibanil®) that activates immunological cells

Kimio Ueno appointed as Representative Director and President (Apr.)

Hiring of university graduate started on regular basis

Established Fukushima Kasei Co., Ltd. (Oct.)

Relocated headquarters to the Kokusai Building in Tokyo;
Constructed Kamakura Plant (Kanagawa Prefecture)

The company name changed to Eiko Kasei Co., Ltd. following the merger of Fukushima Kasei Co., Ltd. and Fukuma Kasei Co., Ltd. (Nov.)

J.J. de Pury appointed as Representative Director and President

Constructed the Fujieda Plant (Shizuoka Prefecture) (Mar.)

Constructed Fukuroi Plant (Shizuoka Prefecture); Established Diagnostics Division

A.F. Leuenberger appointed as Representative Director and President

Launched Picibanil®, an anti-cancer agent and anti-lymphangioma agent (Oct.)